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Background: It remains unclear whether concomitant use of omeprazole attenuates
platelet function in Asian patients with acute coronary syndromes (ACS) receiving
clopidogrel according to cytochrome P450 (CYP) 2C19 phenotype.
Methods: Stent implantation was performed in 177 patients with ACS receiving aspirin
100mg/day and clopidogrel 75mg/day. The platelet reactivity index (PRI) was determined
on admission and average 18 days of after stenting with VASP assay.
Results: On the basis of CYP2C19 genotype, 46 patients (26%) were classified as
extensive metabolizers (EM), 103 (58%) as intermediate metabolizers(IM), and 28 (16%)
as poor metabolizers (PM). There were no significant differences in baseline character-
istics among 3 phenotypes. At baseline, PRI was similar in patients with PPIs and those
without among 3 phenotypes. Among EM, patients with PPIs had higher PRI at 18 days
(4516 vs 3813%; P0.05) and the smaller PRI variation (-45vs-59%, p 0.01)
compared with those without. In contrast, there were no significant differences in PRI
(5518 vs 5315%) and the mean PRI variation (-35%vs-36%) in patients with PPIs and
those without among IM. Similar trends were found in PRI (6910 vs 738%) and the
mean PRI variation (-18vs-15%) among PM (pNS, respectively).
Conclusions: In ACS patients treated with clopidogrel, co-administration of omeprazole
attenuates platelet function in non-carriers, but not in CYP2C19 variant allele carriers.
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Background: Compared with Caucasians, East Asians have shown relatively lower risk
of ischemic events following percutaneous coronary intervention (PCI). The contribution
of multiple risk factors to the occurrence of peri-procedural myocardial infarction (PMI)
in East Asians remains controversial.
Methods: We sought to assess the influence of clinical or laboratory covariates on the
occurrence of PMI in these patients undergoing elective PCI. Stable patients (n  341)
undergoing elective PCI were enrolled. Pre-PCI platelet reactivity was measured by light
transmittance aggregometry (LTA) and the VerifyNow P2Y12 assay. Inflammation
markers (WBC and C-reactive protein) and lipid profile were determined by standard
methods. PMI was defined according to Universal definition [a post-procedural increase
in cardiac biomarker (troponin I and CK-MB)  3 times the 99th percentile of the upper
reference limit]. PMI (defined by troponin I and CK-MB) occurred in 47 (13.8%) and 30
(8.8%) patients, respectively.
Results: There was no significant difference in adenosine diphosphate (ADP)-induced
platelet reactivity between patients with vs. without PMI. Patients with PMI (troponin I)
had higher levels of 6 g/mL collagen-induced platelet aggregation (PA) and VerifyNow
’BASE’ compared with those without PMI. In multivariate analysis, age, stent length, and
low-density lipoprotein (LDL) cholesterol were independent determinants of PMI
(troponin I). The combination of ’6 g/mL collagen-induced PA  40%’ 	 ’BASE 
318’ (odds ratio, 14.08; 95% confidence intervals, 1.68 to 111.11; P  0.015) or ’WBC
 6550/mm3’ 	 ’C-reactive protein  2.3 mg/L’ (odds ratio, 7.75; 95% confidence
intervals, 2.49 to 24.39; P  0.001) was associated with an increased risk of PMI
(troponin I). The greatest likelihood ratio was observed when cholesterol, inflammation
marker and platelet function were combined together.
Conclusions: This is the first study to demonstrate that heightened platelet responsive-
ness to collagen and thrombin may be a risk factor for myonecrosis in patients undergoing
elective PCI. The utility of the combining measures of platelet function, inflammation and
cholesterol to enhance risk stratification and thus facilitate person.
TCT-735
Pharmacodynamic Effect of Adjunctive Cilostazol vs. High-dos Clopidogrel in
Acute Coronary Syndrome Patients According to the CYP2C19 Genotype
(ACCEL-GENOTYPE) study
Young-Hoon Jeong1, Yongwhi Park2, Jin-Sin Koh2, Seok-Jae Hwang2,
Choong Hwan Kwak2, Jin-Yong Hwang2, Udaya Tantry1, Paul Gurbel1
1Sinai Center for Thrombosis Research, Baltimore, MD, 2Gyeongsang National
University Hospital, Jinju, Gyeongsangnam-do
Background: Cilostazol use in ACS patients reduces the risks of ischemic events and
restenosis in East Asians. Compared with Caucasians, East Asians have higher frequency
of CYP2C19 loss-of-function allele (*2 and *3). We compared the pharmacodynamic
effect of adjunctive cilostazol vs. high-dose clopidogrel in PCI-treated East Asians with
ACS according to CYP2C19 genotype.
Methods: ACS patients were assigned to either clopidogrel 150 mg/d (DOUBLE;
n139) or cilostazol 100 mg twice a day 	 clopidogrel 75 mg/d (TRIPLE; n136) on
top of aspirin. Platelet aggregation (PA) was measured at baseline and follow-up (
30-day) with conventional aggregometery and adjusted with known clinical covariates.
Primary endpoint was the level of 20 M ADP-induced PA at follow-up. HPR was
defined as 20 M ADP-induced PA  59%.
Results: During standard-dose clopidogrel, platelet measurements did not differ accord-
ing to individual CYP2C19 genotype between the groups (Fig. A). PA levels and the risk
of HPR increased across CYP2C19 genotype (p  0.174). At follow-up, TRIPLE vs.
DOUBLE showed significantly lower level of PAs irrespective of CYP2C19 genotype
(Fig. B). DOUBLE showed 27.3% of HPR risk, which was increased across CYP2C19
genotype (adjusted p  0.042), whereas TRIPLE effect was not significantly influenced
with CYP2C19 genotype (adjusted p  0.289). Similar trend was observed for
collagen-induced PA.
Conclusions: In PCI-treated East Asians presented with ACS, adjunctive cilostazol to
dual antiplatelet therapy exhibited favorable platelet measurements compared with
high-dose clopidogrel irrespective of CYP2C19 genotype.
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Background: Current guidelines recommend that pts undergoing coronary stenting
receive dual-antiplatelet therapy to prevent acute stent thrombosis. There is limited data on
platelet inhibition in pts presenting with cardiac arrest who require both acute coronary
stenting and therapeutic hypothermia (TH). We sought to determine the extent of platelet
inhibition in pts requiring TH who were treated with clopidogrel.
Methods: We prospectively recruited pts who presented with a cardiac arrest who
required TH and acute coronary stenting. The loading dose of clopidogrel was 600mg
followed by a maintenance dose of 75mg daily administered via a nasogastric tube.
Platelet function was tested at baseline, and at 4, 8, 24, 48, 72, 96 and 120 hrs from the
loading dose of clopidogrel. Platelet activity was analyzed with the VerifyNow point-of-
care rapid platelet function analyzer. Primary endpoint was the extent of platelet inhibition
as a function of time.
Results: We evaluated 8 consecutive patients who received coronary stents and
subsequently required TH. The results of the platelet testing are depicted in the figure
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below. During the period of TH, there was essentially minimal response as 7 out of 8 pts
had 0% of platelet inhibition and 1 patient had marginal response of 7%. Platelet
inhibition became apparent during the re-warming phase but appeared to be relatively
delayed.
Conclusions: In this pilot trial, we found that platelet inhibition with clopidogrel was
minimal during the period of TH. These results raise concerns regarding the potential risks
of stent thrombosis in pts receiving stents and managed with TH.
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Background: Post-treatment platelet reactivity (PR) is associated with ischemic and
bleeding events in patients receiving P2Y12-ADP receptor antagonists.We aimed to the
relationship between post-treatment PR after a 60 mg loading dose of prasugrel and
one-year thrombotic and bleeding events.
Methods: Patients were prospectively included in this observational multicentre study if
they had a successful PCI for an ACS and received prasugrel. VASP index was measured
after prasugrel LD. Endpoint included the rate of thrombotic events (cardiovascular death,
myocardial infarction and stent thrombosis) and bleeding events (TIMI) at one year.
Results: Three hundreds and one patients were enrolled. Nine patients (3%) were lost to
follow-up at one year. The rates of thrombotic and bleeding events at one year were 7.5
and 6.8% respectively. The mean VASP index after a 60mg LD of prasugrel was
3423% and 76 patients (25%) were considered as having high on-treatment platelet
reactivity (HTPR). Patients with HTPR had a higher rate of thrombotic events compared
to good responders (19.7 vs 3.1%;p0.001). Patients with a minor or major non-CABG
related TIMI bleeding had lower PR compared to patients with no bleeding events
(2118 vs 3523%;p0.008). In multivariate analysis, the VASP index predicted both
thrombotic and bleeding events (OR: 1.44 (95% CI: 1.2–1.72; p0.001 and 0.75 (95%
CI: 0.59–0.96;p0.024 (respectively).
Conclusions: Platelet reactivity measurement after prasugrel LD predicts both ischemic
and bleedings events at one year follow-up for ACS patients undergoing PCI.
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Background: Stent thrombosis is a feared complication following stent implantation.
The multi-factorial causes include low anti-platelet response (LR) to the routinely used
drug, clopidogrel. Newer anti-platelet drugs such as prasugrel and ticagrelor have higher
potency with less inter-individual variability in platelet response, however with an
increased bleeding risk. We sought to evaluate the safety and anti-platelet effect of
double-dose clopidogrel as compared with normal-dose prasugrel in patients with
clopidogrel LR undergoing non-urgent PCI.
Methods: TAILOR is a randomized, open-label, single-centre trial. All patients
pre-treated with clopidogrel and undergoing PCI were screened for clopidogrel LR by
whole-blood aggregometry, using the Multiplate analyzer® (Dynabyte, Germany) where
low response to clopidogrel was defined as Multiplate ADP  70 units. Patients
demonstrating LR were randomized to either 150 mg clopidogrel or 10 mg prasugrel (5
mg for patients  75 years or  60 kg).
Results: Of 990 patients screened, 246 (24.9%) exhibited LR to clopidogrel. Of these,
100 (40.5%) were randomized to one of the two regimens (n50 in each group); the
remaining served as controls. Main reasons for non-inclusion were previous stroke,
ongoing anti-coagulant treatment or inability to return for follow up visit. At 1 month,
anti-platelet response was normalized in a total of 67 patients: 37 (75.5%) in the prasugrel
vs 30 (61.2%) in the clopidogrel group (p0.123, unadjusted). Overall, prasugrel resulted
in a greater decrease in Multiplate ADP values (30.121.2 U for prasugrel vs 21.222.4
U for clopidogrel (p0.046)). There were no bleeding episodes, myocardial infarction,
stroke or death during the follow-up.
Conclusions: Tailoring of anti-platelet treatment in patients with clopidogrel LR
undergoing non-urgent PCI translates into improved platelet inhibition with both normal-
dose prasugrel and double-dose clopidogrel, however with a more pronounced effect with
prasugrel.
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Background: Patients with prior coronary artery bypass graft surgery (CABG) who
present with an acute coronary syndrome have high risk for recurrent events. Whether
more intensive antiplatelet therapy with ticagrelor might be beneficial compared to
clopidogrel is unknown. In this substudy of the PLATO trial we studied the effects of
randomized treatment dependent on history of CABG.
Methods: Patients participating in PLATO were classified according to whether they had
prior CABG. The trial’s primary and secondary end points were compared using Cox
proportional hazards regression.
Results: Of the 18,613 study patients, 1,133 (6.5%) had prior CABG, of whom 353
(31%) underwent percutaneous coronary intervention in a saphenous vein graft and 190
(17%) in a native coronary artery. Prior CABG patients had more high risk characteristics
at study entry, experienced more clinical events during follow-up, but had less major
bleeding (Table). The primary endpoint (composite of cardiovascular death, myocardial
infarction, and stroke) was reduced to a similar extent by ticagrelor among patients with
[19.6% vs. 21.4%; hazard ratio (HR), 0.90 (0.69, 1.17)] and without [9.2% vs. 11.0%; HR,
0.84 (0.76, 0.93), Pinteraction0.66] prior CABG. Major bleeding was similar with
ticagrelor vs. clopidogrel among patients with [8.1% vs. 8.7%; HR, 0.93 (0.61, 1.43)] and
without [11.8% vs. 11.4%; HR, 1.04 (0.95, 1.14), Pinteraction0.61] prior CABG.Table:
Outcomes in patients with and without prior coronary artery bypass graft surgery
(CABG).
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